 Home > Biochemistry News > Biotechnology News > Positive interim analysis of Keytruda Phase 3 clinical trial to reduce the risk of recurrence after lung cancer surgery

Positive interim analysis of Keytruda Phase 3 clinical trial to reduce the risk of recurrence after lung cancer surgery

 Last Update: 2022-02-23
 Source: Internet
 Author: User

Tags

assay free thyroxine

keratin conditioning treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Merck & Co.

According to the World Health Organization (WHO), in 2020, lung cancer is the leading cause of cancer death worldwide

Keytruda is an anti-PD-1 monoclonal antibody therapy that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes

The Phase 3 clinical trial enrolled 1177 patients with stage IB-IIIA NSCLC after surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy, randomized 1:1 to receive Keytruda or placebo

The interim analysis also showed an improvement in DFS in patients with tumors that expressed high PD-L1 expression in the Keytruda group compared with the placebo group, although this dual primary endpoint did not reach statistical significance

References:

[1] Merck's Keytruda® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.